Ranawaka Ranthilaka R, Nagahawatte Ajith, Gunasekara Thusitha Aravinda, Weerakoon Hema S, de Silva S H Padmal
a Department of Dermatology , Base Hospital Homagama , Sri Lanka .
b Department of Microbiology , University of Ruhuna , Galle , Sri Lanka , and.
J Dermatolog Treat. 2016 Aug;27(4):364-72. doi: 10.3109/09546634.2015.1119781. Epub 2015 Dec 10.
Nondermatophyte mold (NDM) onychomycosis shows poor response to current topical, oral or device-related antifungal therapies. This study was aimed to determine the efficacy and safety of itraconazole and terbinafine pulse therapy on NDM onychomycosis.
Mycologically proven subjects were treated with itraconazole 400 mg daily or terbinafine 500 mg daily for 7 days/month; two pulses for fingernails and three pulses for toenails(SLCTR/2013/013).
One-hundred seventy-eight patients underwent mycological studies and 148 had positive fungal isolates. NDM were the prevailing fungi, 68.2%, followed by candida species 21.6%, and dermatophytes made up only 10.1%. Out of NDM Aspergillus spp (75.1%) predominated followed by 8.9% Fusarium spp and 4.95% Penicillium spp. The clinical cure at completion of pulse therapy was statistically significant 9.2% versus 2.0% (p < 0.05) in itraconazole group. But no statistically significant difference was detected between the two regimens at the end of 12 months; 65.1% versus 54.64%. Recurrences observed in both groups (6.5% vs. 4.1%) were not statistically significant. With itraconazole pulse 68.22% Aspergillus spp, 50.0% Fusarium spp and 84.6% Penicillium spp showed clinical cure, while terbinafine pulse cured 55.0% Aspergillus spp and 50.0% Fusarium spp.
NDM was the prevailing fungi in onychomycosis in Sri Lanka. Both itraconazole and terbinafine were partially effective on NDM onychomycosis showing a clinical cure of 54-65%. Future research should focus on searching more effective antifungal for NDM onychomycosis.
非皮肤癣菌性霉菌(NDM)甲真菌病对目前的局部、口服或器械相关抗真菌治疗反应不佳。本研究旨在确定伊曲康唑和特比萘芬脉冲疗法治疗NDM甲真菌病的疗效和安全性。
经真菌学证实的受试者,每日口服伊曲康唑400mg或特比萘芬500mg,每月治疗7天;手指甲治疗两个疗程,脚趾甲治疗三个疗程(SLCTR/2013/013)。
178例患者接受了真菌学研究,148例真菌分离培养阳性。NDM是主要真菌,占68.2%,其次是念珠菌属,占21.6%,皮肤癣菌仅占10.1%。在NDM中,曲霉菌属(75.1%)占主导,其次是镰刀菌属(8.9%)和青霉菌属(4.95%)。脉冲治疗结束时,伊曲康唑组的临床治愈率具有统计学意义,为9.2%,而另一组为2.0%(p<0.05)。但在12个月结束时,两种治疗方案之间未检测到统计学上的显著差异,分别为65.1%和54.64%。两组观察到的复发率(6.5%对4.1%)无统计学意义。伊曲康唑脉冲治疗后,68.22%的曲霉菌属、50.0%的镰刀菌属和84.6%的青霉菌属显示临床治愈,而特比萘芬脉冲治疗使55.0%的曲霉菌属和50.0%的镰刀菌属治愈。
NDM是斯里兰卡甲真菌病中的主要真菌。伊曲康唑和特比萘芬对NDM甲真菌病均有部分疗效,临床治愈率为54%-65%。未来的研究应集中于寻找更有效的治疗NDM甲真菌病的抗真菌药物。